NCT02059031View on ClinicalTrials.gov

A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

GSK1265744 Reference formulation

GSK1265744 (micronized) reference formulation is available as 30 mg tablet to be orally administered with 240 mL of water

DRUG

GSK1265744 New formulation 1

GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water

DRUG

GSK1265744 New formulation 2

GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water

Trial Locations (1)

66211

GSK Investigational Site, Overland Park

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY